C3660996_interactsWith_C2981815 | Knowledge4COVID-19

Property	Value
?:effect	<https://research.tib.eu/covid-19/entity/C0001688>
?:hasPrimarySource	<https://research.tib.eu/covid-19/SourceName/UMLS>
?:impact	increase
?:interaction	The risk or severity of adverse effects can be increased when Dupilumab is combined with Dalantercept.
?:objectDrug	<https://research.tib.eu/covid-19/entity/C2981815>
?:object_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB14988>
?:precipitantDrug	<https://research.tib.eu/covid-19/entity/C3660996>
?:precipitant_hasDrugBankID	<https://research.tib.eu/covid-19/entity/DB12159>
is ?:subClassOf of	<https://research.tib.eu/covid-19/entity/C3660996_hasPharmacodynamic_C2981815>
?:type	<https://research.tib.eu/covid-19/vocab/DrugDrugInteraction>

Metadata

Anon_0

expand all